Which has the lower trailing P/E, ABUS or RIGL?

RIGL has the lower trailing P/E: ABUS trades at 5.69 and RIGL at 2.85. P/E is one valuation measure and does not by itself establish which business is cheaper.

Which has grown faster, ABUS or RIGL?

Over the past five years, ABUS grew revenue faster — ABUS at a 85.17% CAGR versus RIGL at 13.94%.

Is ABUS or RIGL more profitable?

RIGL runs the higher net margin — ABUS at 84.23% versus RIGL at 116.30%.

How have ABUS and RIGL total returns compared?

Over the past 10 years, ABUS delivered 2.93% and RIGL delivered 1.77% annualized total return. Past performance doesn't predict future results.

Arbutus Biopharma Corp (ABUS) vs Rigel Pharmaceuticals, Inc. (RIGL)

A side-by-side comparison of Arbutus Biopharma Corp and Rigel Pharmaceuticals, Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.

ABUS

Arbutus Biopharma Corp

$877M

$4.44HealthcareDelayed quote: Oct 6, 2026, 1:55 PM EDT

RIGL

Rigel Pharmaceuticals, Inc.

$860M

$46.50HealthcareDelayed quote: Oct 6, 2026, 1:54 PM EDT

Total return — ABUS vs RIGL

growth of $100 · dividends reinvested · last 10y

ABUS +45.9% (+3.9%/yr)RIGL +26.8% (+2.4%/yr)ABUS compounded faster over this window

ABUS RIGL

ABUS vs RIGL: by the numbers

•ABUS is the larger company ($877M vs $860M market cap).
•RIGL trades at the lower trailing earnings multiple (2.85 vs 5.69 P/E), one valuation lens rather than an overall verdict.
•RIGL converts more revenue to profit (116.30% vs 84.23% net margin).
•ABUS grew revenue faster over the past five years (85.17% vs 13.94% CAGR).

Metrics side by side

Valuation

Metric	ABUS	RIGL
P/E ratio	5.69	2.85
Forward P/E	6.00	13.56
P/S ratio	4.83	3.11
P/B ratio	3.39	2.02
EV / EBITDA	5.85	9.36
FCF yield	N/A	9.23%

Profitability

Metric	ABUS	RIGL
Gross margin	99.98%	91.39%
Operating margin	-192.08%	42.63%
Net margin	84.23%	116.30%
ROE	59.16%	75.67%
ROIC	54.39%	18.72%

Growth (annualized)

Metric	ABUS	RIGL
Revenue CAGR (5Y)	85.17%	13.94%
Total return CAGR (5Y)	2.19%	6.25%

Frequently asked

Which has the lower trailing P/E, ABUS or RIGL?: RIGL has the lower trailing P/E: ABUS trades at 5.69 and RIGL at 2.85. P/E is one valuation measure and does not by itself establish which business is cheaper.
Which has grown faster, ABUS or RIGL?: Over the past five years, ABUS grew revenue faster — ABUS at a 85.17% CAGR versus RIGL at 13.94%.
Is ABUS or RIGL more profitable?: RIGL runs the higher net margin — ABUS at 84.23% versus RIGL at 116.30%.
How have ABUS and RIGL total returns compared?: Over the past 10 years, ABUS delivered 2.93% and RIGL delivered 1.77% annualized total return. Past performance doesn't predict future results.

Go deeper

Full ABUS analysis Full RIGL analysis Interactive comparison tool

Dig into the metrics

Arbutus Biopharma P/E ratio Rigel Pharmaceuticals P/E ratio Arbutus Biopharma ROE Rigel Pharmaceuticals ROE Arbutus Biopharma operating margin Rigel Pharmaceuticals operating margin Arbutus Biopharma revenue growth Rigel Pharmaceuticals revenue growth Arbutus Biopharma free cash flow Rigel Pharmaceuticals free cash flow

Arbutus Biopharma & Rigel Pharmaceuticals appear in these rankings

Fastest Revenue Growth Stocks Highest ROE Stocks Highest ROIC Stocks Highest Operating Margin Stocks

Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.